All News

Found 5,927 articles

• XNK Therapeutics to present at Investival Showcase Meeting - November 10, 2023

  11/10/2023

  XNK Therapeutics AB announced that Johan Liwing, CEO, will present the company at the at Investival Showcase Meeting in London, on November 13th

• Cantargia Publishes Interim Report for Third Quarter 2023

  11/10/2023

  Cantargia Cantargia AB's interim report for the period January until September 2023 is now available on the company's web page

• March Biosciences and Cancer Focus Fund Announce $4.8 Million Investment to Support a Phase 2 Clinical Trial of Novel CAR-T Therapy for T-Cell Lymphoma

  11/9/2023

  March Biosciences and Cancer Focus Fund, LP announced that Cancer Focus Fund is investing $4.8 million in funding and providing clinical support for March Bio's upcoming Phase 2 clinical trial of MB-105 for the treatment of relapsed T-cell leukemias and lymphomas.

• Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

  11/9/2023

  Affimed N.V. announced that the International Nonproprietary Names Expert Committee of the World Health Organization has selected "acimtamig" for the nonproprietary name of the Company’s investigational drug for CD30-positive Lymphomas, previously known as AFM13.

• Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

  11/9/2023

  Aprea Therapeutics, Inc. reported financial results for the three and nine months ended September 30, 2023, and provided a business update.

• Aptose Reports Results for the Third Quarter 2023

  11/9/2023

  Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced financial results for the three months and nine months ended September 30, 2023, and provided a corporate update.

• Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

  11/9/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2023, and highlighted recent business updates.

• American Brain Tumor Association Announces $1.3 Million in New Funding to Accelerate Adult and Pediatric Brain Tumor Research

  11/8/2023

  The American Brain Tumor Association announced the funding of $1.37 million towards 23 new research grants to advance brain tumor science and treatments, across all brain tumor types and ages.

• bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy

  11/8/2023

  bit.bio, the company coding human cells for novel cures, announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter clinical development in 2025.

• Solid Biosciences Provides Third Quarter Business Update and Financial Results

  11/8/2023

  Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

• ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

  11/7/2023

  ADC Therapeutics SA reported financial results for the third quarter 2023 and provided business updates.

• Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers

  11/7/2023

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.

• Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

  11/7/2023

  Salarius Pharmaceuticals, Inc. announces that it participated in a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration to receive guidance regarding the development program for seclidemstat to treat Ewing sarcoma.

• ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer

  11/6/2023

  ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, announced the appointment of Patricia Turney as Chief Technical Operations Officer.

• Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

  11/6/2023

  Cellectis, a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, provided business updates and financial results for the nine-month period ending September 30, 2023.

• Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

  11/6/2023

  Portage Biotech Inc. today announced the presentations of updates from its ongoing IMPORT-201 Phase 1/2 trial of PORT-2 (IMM60), an invariant natural killer T cell (iNKT) engager for patients with NSCLC and advanced melanoma, and its ADPORT-601 adaptive Phase 1a/1b trial for PORT-6 (A2A inhibitor) and PORT-7 (A2B inhibitor) in multiple solid tumors at SITC.

• Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023

  11/6/2023

  Innovent Biologics, Inc. presents latest data of two ophthalmic bispecific antibodies at the American Academy of Ophthalmology 2023 Annual Meeting, including a Phase 2 clinical study of anti-VEGF and anti-complement bispecific fusion protein for neovascular age-related macular degeneration and a Phase 1 clinical study of anti-VEGF-A/Ang-2 bispecific antibody for diabetic macular edema.

• XNK Therapeutics announces poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

  11/6/2023

  XNK Therapeutics AB participates in the SITC meeting, which takes place in San Diego, USA, and will present the latest research relating to the company's leading natural killer cell therapies.

• Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

  11/6/2023

  Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced data presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held on November 1-5, 2023.

• Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

  11/4/2023

  TriSalus Life Sciences® Inc. presented additional Phase 1 clinical data during the late-breaker oral presentation session at the Society of Immunotherapy for Cancer 2023 Annual Meeting.